Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection? A retrospective cohort study

Hsiang Ling Wu, Ying Hsuan Tai, Wen Kuei Chang, Kuang Yi Chang, Mei Yung Tsou, Yih Giun Cherng, Shih Pin Lin

研究成果: 雜誌貢獻文章

摘要

Whether morphine used in human cancer surgery would exert tumor-promoting effects is unclear. This study aimed to investigate the effects of morphine dose on cancer prognosis after colorectal cancer (CRC) resection.In a retrospective study, 1248 patients with stage I through IV CRC undergoing primary tumor resections and using intravenous patient-controlled analgesia for acute surgical pain at a tertiary center between October 2005 and December 2014 were evaluated through August 2016. Progression-free survival (PFS) and overall survival (OS) were analyzed using proportional hazards regression models.Multivariable analysis demonstrated no dose-dependent association between the amount of morphine dose and PFS (adjusted hazard ratio, HR=1.31, 95% confidence interval, CI=0.85-2.03) or OS (adjusted HR=0.86, 95% CI=0.47-1.55). Patients were further classified into the high-dose and low-dose groups by the median of morphine consumption (49.7mg), and the morphine doses were mean 75.5 ± standard deviation 28.8mg and 30.1±12.4mg in high-dose and low-dose groups, respectively. Multivariable models showed no significant difference in PFS or OS between groups, either (adjusted HR=1.24, 95% CI=0.97-1.58 for PFS; adjusted HR=1.01, 95% CI=0.71-1.43 for OS).Our results did not support a definite association between postoperative morphine consumption and cancer progression or all-cause mortality in patients following CRC resection.

原文英語
文章編號e15442
期刊Medicine (United States)
98
發行號18
DOIs
出版狀態已發佈 - 五月 1 2019

指紋

Acute Pain
Morphine
Colorectal Neoplasms
Cohort Studies
Retrospective Studies
Disease-Free Survival
Survival
Neoplasms
Patient-Controlled Analgesia
Proportional Hazards Models
Confidence Intervals
Mortality

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection? A retrospective cohort study. / Wu, Hsiang Ling; Tai, Ying Hsuan; Chang, Wen Kuei; Chang, Kuang Yi; Tsou, Mei Yung; Cherng, Yih Giun; Lin, Shih Pin.

於: Medicine (United States), 卷 98, 編號 18, e15442, 01.05.2019.

研究成果: 雜誌貢獻文章

@article{a8746fa9f49d4de89ce2b54fbad09163,
title = "Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection?: A retrospective cohort study",
abstract = "Whether morphine used in human cancer surgery would exert tumor-promoting effects is unclear. This study aimed to investigate the effects of morphine dose on cancer prognosis after colorectal cancer (CRC) resection.In a retrospective study, 1248 patients with stage I through IV CRC undergoing primary tumor resections and using intravenous patient-controlled analgesia for acute surgical pain at a tertiary center between October 2005 and December 2014 were evaluated through August 2016. Progression-free survival (PFS) and overall survival (OS) were analyzed using proportional hazards regression models.Multivariable analysis demonstrated no dose-dependent association between the amount of morphine dose and PFS (adjusted hazard ratio, HR=1.31, 95{\%} confidence interval, CI=0.85-2.03) or OS (adjusted HR=0.86, 95{\%} CI=0.47-1.55). Patients were further classified into the high-dose and low-dose groups by the median of morphine consumption (49.7mg), and the morphine doses were mean 75.5 ± standard deviation 28.8mg and 30.1±12.4mg in high-dose and low-dose groups, respectively. Multivariable models showed no significant difference in PFS or OS between groups, either (adjusted HR=1.24, 95{\%} CI=0.97-1.58 for PFS; adjusted HR=1.01, 95{\%} CI=0.71-1.43 for OS).Our results did not support a definite association between postoperative morphine consumption and cancer progression or all-cause mortality in patients following CRC resection.",
keywords = "cancer surgery, metastasis, opioid, recurrence",
author = "Wu, {Hsiang Ling} and Tai, {Ying Hsuan} and Chang, {Wen Kuei} and Chang, {Kuang Yi} and Tsou, {Mei Yung} and Cherng, {Yih Giun} and Lin, {Shih Pin}",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MD.0000000000015442",
language = "English",
volume = "98",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "18",

}

TY - JOUR

T1 - Does postoperative morphine consumption for acute surgical pain impact oncologic outcomes after colorectal cancer resection?

T2 - A retrospective cohort study

AU - Wu, Hsiang Ling

AU - Tai, Ying Hsuan

AU - Chang, Wen Kuei

AU - Chang, Kuang Yi

AU - Tsou, Mei Yung

AU - Cherng, Yih Giun

AU - Lin, Shih Pin

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Whether morphine used in human cancer surgery would exert tumor-promoting effects is unclear. This study aimed to investigate the effects of morphine dose on cancer prognosis after colorectal cancer (CRC) resection.In a retrospective study, 1248 patients with stage I through IV CRC undergoing primary tumor resections and using intravenous patient-controlled analgesia for acute surgical pain at a tertiary center between October 2005 and December 2014 were evaluated through August 2016. Progression-free survival (PFS) and overall survival (OS) were analyzed using proportional hazards regression models.Multivariable analysis demonstrated no dose-dependent association between the amount of morphine dose and PFS (adjusted hazard ratio, HR=1.31, 95% confidence interval, CI=0.85-2.03) or OS (adjusted HR=0.86, 95% CI=0.47-1.55). Patients were further classified into the high-dose and low-dose groups by the median of morphine consumption (49.7mg), and the morphine doses were mean 75.5 ± standard deviation 28.8mg and 30.1±12.4mg in high-dose and low-dose groups, respectively. Multivariable models showed no significant difference in PFS or OS between groups, either (adjusted HR=1.24, 95% CI=0.97-1.58 for PFS; adjusted HR=1.01, 95% CI=0.71-1.43 for OS).Our results did not support a definite association between postoperative morphine consumption and cancer progression or all-cause mortality in patients following CRC resection.

AB - Whether morphine used in human cancer surgery would exert tumor-promoting effects is unclear. This study aimed to investigate the effects of morphine dose on cancer prognosis after colorectal cancer (CRC) resection.In a retrospective study, 1248 patients with stage I through IV CRC undergoing primary tumor resections and using intravenous patient-controlled analgesia for acute surgical pain at a tertiary center between October 2005 and December 2014 were evaluated through August 2016. Progression-free survival (PFS) and overall survival (OS) were analyzed using proportional hazards regression models.Multivariable analysis demonstrated no dose-dependent association between the amount of morphine dose and PFS (adjusted hazard ratio, HR=1.31, 95% confidence interval, CI=0.85-2.03) or OS (adjusted HR=0.86, 95% CI=0.47-1.55). Patients were further classified into the high-dose and low-dose groups by the median of morphine consumption (49.7mg), and the morphine doses were mean 75.5 ± standard deviation 28.8mg and 30.1±12.4mg in high-dose and low-dose groups, respectively. Multivariable models showed no significant difference in PFS or OS between groups, either (adjusted HR=1.24, 95% CI=0.97-1.58 for PFS; adjusted HR=1.01, 95% CI=0.71-1.43 for OS).Our results did not support a definite association between postoperative morphine consumption and cancer progression or all-cause mortality in patients following CRC resection.

KW - cancer surgery

KW - metastasis

KW - opioid

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85065552799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065552799&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000015442

DO - 10.1097/MD.0000000000015442

M3 - Article

C2 - 31045812

AN - SCOPUS:85065552799

VL - 98

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 18

M1 - e15442

ER -